Tests psiguavin, a guava-derived compound, for weight loss in people with obesity
Tests a guava-derived supplement against placebo in adults with obesity or overweight.
Plain-language title generated from the registry record
Registry title: Effect of Psiguavin for Obesity Treatment (PSIGUAVIN)
Key facts
- Where
- Murcia, SpainSee the site
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06512818, who can take part
Where in Spain
- Faculty of Nursing. Catholic University of MurciaMurcia, SpainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Universidad Católica San Antonio de Murcia
- Trial code
- NCT06512818
- Record updated
- 22 July 2024
- Original description
The main objective of the project focuses on the study of the effectiveness of a functional component extracted from Psidium guava, psiguavin, as a potential inhibitor of pancreatic lipase and, therefore, as an adjuvant for the treatment of obesity.Read full original descriptionShow less
Effect of Psiguavin, a Bioactive Compound Derived From Psidium Guava, as Therapeutic Agent for Obesity Treatment
The main objective of the project focuses on the study of the effectiveness of a functional component extracted from Psidium guava, psiguavin, as a potential inhibitor of pancreatic lipase and, therefore, as an adjuvant for the treatment of obesity.
That is, the aim is to verify from various experimental perspectives the effect of psiguavin on the activity of the enzyme pancreatic lipase (EC 3.1.1.3), which is the main enzyme responsible for the digestion of lipids from the diet. Our preliminary studies have shown that there is a strong interaction between psiguavin and the active center of pancreatic lipase; however, it is necessary to confirm these initial hypotheses through a clinical trial. Taking into account that the usefulness of this compound is based on the reduction of dietary calorie intake, in order to confirm its therapeutic usefulness, a clinical trial will be proposed.
To this end, the following specific objective is defined, which is intended to be achieved with the execution of the project:
• Evaluate the effect of psiguavin on weight loss of people with overweight/obese people.
Inclusion: Being between 18 and 65 years old; Having a BMI between 25 and 40; Voluntarily taking part in the study.
Exclusion: Have been on a diet for at least 6 months before the start of the study; Taking chronic medication that can alter metabolism (thyroid drugs, corticosteroids, etc.); Having an intestinal chronic disease; Having a contraindication for guava; Being pregnant.